Safety Profile
Vasopressin
Updated today
Regulatory Status
Safety Summary
- Essential critical care medication
- decades of safe use
- well-characterized
Vasopressin sits in our well-studied tier (9/10). The safety dataset is robust, mechanisms are characterized, and side-effect patterns are predictable. Researchers working with this compound should still verify vendor COA quality — a clean safety profile means nothing if the vial contains the wrong compound or is under-dosed.
Methodology
How we rate peptide safety
Every compound in our index gets a 1–10 safety score based on four weighted factors. The score reflects known research-use risk — not medical advice.
- 40% — Clinical evidence. Volume of peer-reviewed trials, sample sizes, duration, and consistency of outcomes. FDA-approved compounds anchor the top end (8–10); preclinical-only compounds cap at 6.
- 30% — Adverse-event profile. Severity and frequency of reported side effects, including GI events, cardiovascular signals, hypoglycemia, and long-term organ effects.
- 20% — Regulatory status. FDA approval, EMA approval, or status in active clinical trials. Compounds under safety warnings are penalized.
- 10% — Community-reported outcomes. Reddit, forum, and published case-report signal beyond formal trials. Used as a late-stage tiebreaker, not a leading factor.
Related compounds
Other compounds researchers compare with Vasopressin
Safety ratings are derived from published clinical data, FDA approval status, and community-reported outcomes. They are not medical advice. Always consult a healthcare professional before using any research compound.
